Investigating how certain metabolites signal danger in acute lung injury
Indole Metabolites as Xenobiotic Danger signals in Acute Lung Injury
This study is looking at how certain substances in the lungs can signal problems during acute respiratory distress syndrome (ARDS) and how they affect the immune system, with the goal of finding new ways to help people with ARDS feel better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11175788 on NIH RePORTER |
What this research studies
This research focuses on understanding how specific metabolites act as danger signals in the lungs during acute respiratory distress syndrome (ARDS). The study aims to explore the interactions between these signals and the immune response in lung epithelial cells, which are crucial for maintaining lung function. By examining the biological pathways involved, the research seeks to identify potential therapeutic targets that could improve outcomes for patients suffering from ARDS. The approach includes analyzing the inflammatory responses triggered by these metabolites and their effects on lung health.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults experiencing acute respiratory distress syndrome or those at high risk for developing ARDS.
Not a fit: Patients with chronic lung diseases or those not experiencing acute respiratory distress may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce inflammation and improve survival rates for patients with acute lung injury.
How similar studies have performed: Previous research has shown promise in understanding the role of danger signals in other inflammatory conditions, suggesting potential for success in this novel approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Evankovich, John W — University of Pittsburgh at Pittsburgh
- Study coordinator: Evankovich, John W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.